Boiron Valuation Multiples

Boiron Overview

About Boiron

Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.

Founded

1932

HQ

Employees

2.8K

Website

boiron.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $592M

EBITDA: $94M

EV

$467M

Valuation Multiples

Multiples.vc

Start free trial

Boiron Financials

Boiron reported last 12-month revenue of $592M and EBITDA of $94M.

In the same LTM period, Boiron generated $94M in EBITDA and $35M in net income.

Boiron P&L

In the most recent fiscal year, Boiron reported revenue of $574M and EBITDA of $69M.

Boiron expects next 12-month revenue of XXX and NTM EBITDA of XXX

Boiron Stock Performance

Boiron has current market cap of $520M, and enterprise value of $467M.

Boiron's stock price is $29.93.

Boiron Valuation Multiples

Boiron trades at 0.8x EV/Revenue multiple, and 5.0x EV/EBITDA.

Boiron Financial Valuation Multiples

As of April 18, 2026, Boiron has market cap of $520M and EV of $467M.

Equity research analysts estimate Boiron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Boiron has a P/E ratio of 15.0x.

Boiron Margins & Growth Rates

Boiron's revenue in the last 12 month grew by 5%.

Boiron's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Boiron's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Boiron's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Boiron Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Boiron M&A Activity

Boiron acquired XXX companies to date.

Last acquisition by Boiron was on XXXXXXXX, XXXXX. Boiron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Boiron Investment Activity

Boiron invested in XXX companies to date.

Boiron made its latest investment on XXXXXXXX, XXXXX. Boiron invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).